Page last updated: 2024-08-24

bromfenac and ximelagatran

bromfenac has been researched along with ximelagatran in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Ekins, S; Williams, AJ; Xu, JJ1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Temple, R1
Senior, JR1

Reviews

1 review(s) available for bromfenac and ximelagatran

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for bromfenac and ximelagatran

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Hy's law: predicting serious hepatotoxicity.
    Pharmacoepidemiology and drug safety, 2006, Volume: 15, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Azetidines; Benzophenones; Benzylamines; Bilirubin; Biomarkers; Bromobenzenes; Chemical and Drug Induced Liver Injury; Chromans; Drug Approval; Humans; Hypoglycemic Agents; Liver; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Assessment; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration

2006
How can 'Hy's law' help the clinician?
    Pharmacoepidemiology and drug safety, 2006, Volume: 15, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Azetidines; Benzophenones; Benzylamines; Bilirubin; Biomarkers; Bromobenzenes; Chemical and Drug Induced Liver Injury; Chromans; Drug Approval; Humans; Hypoglycemic Agents; Liver; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Assessment; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration

2006